Abstract
Introduction: Colon Cancer is one of leading cancer that causes morbidity and mortality worldwide, causes 774,000 deaths. Fucoxanthin contained brown seaweed Bory) extracts showed cytotoxic activity by and study, including colon cancer. This study aims to examine the absorption profile of fucoxanthin in blood plasma on colon cancer model mice. Methods: Mice were induced by azoxymethane (AOM) and two cycle dextran sulfate sodium (DSS). Mice were given an extract of brown seaweed Bory that contain fucoxanthin. Fucoxanthin content in blood plasma analyzed using mobile phase methanol: acetonitrile by Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) analysis. Results: The maximum concentration of fucoxanthin in blood was at 4 hours after administration, and the plasma concentration is 2.15 nmol/L, T1/2 6.25 h, and AUC 10.75 nmol/L/h Conclusions: The method was applied successfully in a pharmacokinetic study and the resulting oral brown seaweed bioavailability calculated.
| Original language | English |
|---|---|
| Pages (from-to) | 567-570 |
| Number of pages | 4 |
| Journal | Pharmacognosy Journal |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 May 2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Brown seaweed
- Colon cancer
- Fucoxanthin
Fingerprint
Dive into the research topics of 'Preliminary of pharmacokinetics study of brown seaweed (turbinaria decurrens bory) extract in colon cancer model mice induced by aom (azoxymethane) and dss (dextran sodium sulphate)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver